Dr Eduardo Jones, PHD in Hawi, HI - Psychologist

Dr Eduardo Jones, PHD is a Psychologist - Clinical based in Hawi, Hawaii. Dr Eduardo Jones is licensed to practice in Hawaii (license number PSY-1763) and his current practice location is 55-3406 Akoni Pule Hwy, Hawi, Hawaii. He can be reached at his office (for appointments etc.) via phone at (808) 209-2263.

NPI number for Dr Eduardo Jones is 1538592795 and his current mailing address is Po Box 1023, Kapaau, Hawaii. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1538592795.

Contact Information

	Dr Eduardo Jones, PHD
	55-3406 Akoni Pule Hwy, Hawi, HI 96719
	(808) 209-2263
	(833) 402-1821

Healthcare Provider's Profile

Full Name	Dr Eduardo Jones
Gender	Male
Speciality	Psychologist - Clinical
Location	55-3406 Akoni Pule Hwy, Hawi, Hawaii
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1538592795
Provider Enumeration Date: 08/12/2013
Last Update Date: 10/18/2022

Medical Identifiers

Medical identifiers for Dr Eduardo Jones such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1538592795	NPI	-	NPPES
830895	Medicaid	HI

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103TC0700X	Psychologist - Clinical	PSY-1763 (Hawaii)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Eduardo Jones is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Eduardo Jones, PHD Po Box 1023, Kapaau, HI 96755-1023 Ph: (808) 209-2263	Dr Eduardo Jones, PHD 55-3406 Akoni Pule Hwy, Hawi, HI 96719 Ph: (808) 209-2263

News Archive

Six-gene signature predicts survival after targeted therapy for NSCLC

The presence of a six-gene profile in the microRNA of patients with advanced non-squamous non-small-cell lung cancer predicts reduced survival likelihood after first-line treatment with targeted therapy followed by chemotherapy for disease progression, indicate research results.

State-of-the-art laparoscopic robotic technology sends most prostate patients home the day after surgery

As recently as three years ago, the gold standard to treat prostate cancer, the second most common form of cancer in men, was an invasive surgery that required up to a one-week hospital stay.

Polls show more teen girls see "alcopop" ads than women age 31-44

The American Medical Association (AMA) released the results of two nationwide polls today that reveal the extent of underage consumption and marketing exposure to "alcopops" or so-called "girlie drinks." The AMA expressed concern that hard-liquor brands are using these sweet-flavored malt beverages as "gateway" beverages to attract less-experienced drinkers.

IRIS International announces approval of share repurchase program

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that, effective immediately, its Board of Directors has approved a repurchase program for up to $10 million in shares of the Company's common stock over a twelve month period.

Dr Eduardo Jones, PHD - Psychologist in Hawi, HI